Oppenheimer reiterates Salesforce stock rating after investor day

Oppenheimer reiterated an Outperform rating and $275 price target on Salesforce, whose shares were trading at $250.54, after management reaffirmed its fiscal 2030 revenue target of $63 billion. The target implies an 11% revenue CAGR and at least a 39% operating margin, supported by a 77% trailing-12-month gross margin and expected reacceleration in organic growth. Analysts cited AIforce, Claudeforce and Headless as potential AI monetization catalysts; 34 analysts have recently raised earnings estimates, although Oppenheimer characterized the investor day as uninspiring overall.

Analysis

The investable issue is not the long-range revenue target but whether AI can lift net revenue retention and attach rates before incremental compute, sales capacity, and partner incentives absorb the gross-profit benefit. CRM’s installed-base distribution gives it an advantage over point AI vendors: embedding workflow agents into system-of-record data can reduce customer acquisition costs and raise switching costs. Conversely, customers may consolidate spend into Microsoft (MSFT) or ServiceNow (NOW) if CRM’s AI products are perceived as feature parity rather than a measurable labor-productivity product.

Near term, the investor-day setup is vulnerable to a "show-me" reaction: broad analyst target support and upward estimate revisions leave limited room for another multiple expansion absent disclosed paid-adoption, pricing realization, or backlog metrics. Over the next 1-3 months, watch quarterly cRPO, remaining-performance-obligation growth, net new ARR, and the rate at which subscription growth reaccelerates; these are more probative than management’s multi-year margin aspiration. A downside catalyst would be enterprise IT budget scrutiny or AI-related discounting, which would expose a gap between headline pricing tiers and realized revenue per seat.

Over 6-18 months, successful cross-cloud AI adoption would be most damaging to standalone customer-service and sales-enablement vendors with narrower data estates, while potentially expanding CRM’s share of enterprise software budgets. The contrarian view is that consensus is treating AI as a clean margin and valuation tailwind; enterprise deployments often require costly implementation, data cleanup, and outcome guarantees, so services/partner economics could delay margin conversion even if bookings improve. The thesis is falsified if CRM demonstrates sustained subscription-growth acceleration alongside stable or rising operating margin, rather than growth purchased through discounting or elevated go-to-market spend.

Key Decisions for Investors

• Maintain a modest long CRM only on evidence-based confirmation: add following a quarterly cRPO and subscription-revenue acceleration with no operating-margin giveback. Target a 6-12 month rerating toward higher-quality large-cap software peers; exit or hedge if bookings improve but deferred-revenue indicators and realized pricing do not.
• Use a 1-3 month relative-value expression rather than outright beta: long CRM / short a basket weighted to narrower CRM-adjacent software exposure (for example, ZI and FIVN), sized beta-neutral. The payoff requires AI cross-sell to favor the platform; cover if CRM’s AI disclosures remain qualitative while point-solution demand or guidance improves.
• Do not underwrite the long solely from published price targets or a long-dated revenue framework. Set an alert for disclosed paid AI customers, AI ARR/attach rate, and sales-cycle duration at the next earnings release; absent these metrics, treat the AI monetization claim as unverified and avoid adding into pre-earnings strength.
• For downside protection around the next results, consider a CRM put spread financed only opportunistically after a sharp pre-earnings rally, with a 2-3 month expiry. The catalyst is a failure of forward subscription or cRPO commentary to validate reacceleration; risk is a credible quantitative AI monetization disclosure triggering a gap higher.